Brand Reference: Uloric
| Metric | Verified Benchmark | Source |
|---|---|---|
| Febuxostat RxNorm Concept ID | 608785 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $185.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $12.60 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $16.00 / mo | 13 Zero-PHI Verified Patient Logs |
Thiazolecarboxylic non-purine structure that sterically plugs the narrow molybdenum-pterin channel of both oxidized and reduced xanthine oxidase without affecting other purine/pyrimidine enzymes—safe in CKD stage 3 without HLA-B*5801 cross-reactivity.
Classified under Non-Purine Selective Oxidized/Reduced Xanthine Oxidase Inhibitor (Rx), Febuxostat exhibits a $172.40/month gap between standard U.S. retail cash counters ($185.00) and verified direct-to-patient routing ($12.60) anchored to $0.3800 CMS unit cost.
Pharmacokinetic profiling of Febuxostat demonstrates an elimination half-life of 5–8 hours with 49% oral systemic bioavailability; clearance proceeds via hepatic ugt1a1/1a8/1a9 glucuronidation and cyp1a2/2c8 oxidation (dual biliary/renal clearance), reaching clinical onset within 2 weeks >45% serum urate drop.
Titration schedules for Febuxostat (40 mg PO once daily → 80 mg PO once daily) require excluding concomitant azathioprine or mercaptopurine (fatal myelosuppression); real-world patient logs highlight arthralgia (7% of reports), alt elevation (6% of reports), nausea (5% of reports) alongside a 85.70% Worth-It consensus.
Across 13 verified cash-pay logs, Febuxostat achieves a 85.70% Worth-It rating with out-of-pocket spend averaging $16.00/mo versus $185.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 40 mg PO once daily for Febuxostat; monthly out-of-pocket dropped to $11.09 compared with $185.00 retail.
Completed 10 weeks on Febuxostat (80 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 40 mg PO once daily Febuxostat sourced via Local Pharmacy ($14.62/mo cash pay without insurance prior authorization).